Neoadjuvant Toripalimab Plus Nimotuzumab in Oral Squamous Cell Carcinoma Prior to Radical Therapy

NCT05803915 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

57

Enrollment

OTHER

Sponsor class

Conditions

Oral Squamous Cell Carcinoma

Interventions

DRUG: Toripalimab

Sponsor

Peking Union Medical College Hospital